<DOC>
	<DOCNO>NCT01175330</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Polyunsaturated Fatty Acid prevention Atrial Fibrillation anti-inflammatory effect patient CABG surgery</brief_summary>
	<brief_title>Omega 3 Fatty Acid Efficiency Prevention Atrial Fibrillation After Coronary Artery Bypass Grafting</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<criteria>Elective CABG surgery . Signed , document informed consent prior admission study . Unstable angina , require intervention CABG &lt; 24 hr screening . Decompensated congestive heart failure . Chronic , persistent , paroxysmal atrial fibrillation . Uncorrected significant valvular heart disease Known hypersensitivity study drug Left ventricular dysfunction ( ejection fraction &lt; 35 % ) Use antiarrhythmic drug beta blocker Noncardiac illness life expectancy le 1 year Bleeding diathesis history coagulopathy Significant renal liver insufficiency Significant thyroid , pulmonary disease Uncontrolled diabetes mellitus Patients antiarrhythmic drug Patients pacemaker Patients unable provide/sign inform consent . Patients currently take marine base omegathree fish oil supplement . Disturbances lipid metabolism , serum triglyceride value &gt; 3 mmol/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Omega-3 fatty acid</keyword>
	<keyword>Ischemic Heart Disease</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Subcutaneous cardiac monitoring</keyword>
</DOC>